Thank you for all of the wonderful responses we received about the Food and Drug Administration’s (FDA) approval of a drug for patients with advanced metastatic breast cancer. It's not always easy to decide which research has legs and is worth investing in— and I take that task seriously— but when something you believe in succeeds, the reward and sense of inspiration that follows can be immense. The FDA’s approval of Ibrance (palbociclib), a drug that the Noreen Fraser Foundation (NFF) helped fund the development for, did just that.
I have been fighting breast cancer for 13 years, and during that time I have done my homework. I have pored through research, and I have become familiar with the various institutions that are working in the breast cancer arena.